Analyst Price Targets — ACAD
Latest News for ACAD
Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the
BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,515,173 shares of the biopharmaceutical company's stock, valued at approximately $569,634,000. BlackRock Inc. owned 13.15% of ACADIA Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACAD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.